Invivoscribe, the Leading diagnostics research for Leukemias, Lymphomas and blood diseases. We provides access to cutting edge testing to physicians and cancer centers world wide, enabling doctors to determine the most successful method of treatment for each patient.
Invivoscribe provides a comprehensive selection of PCR-based gene rearrangement, chromosome translocation, and gene mutation Research Use Only testing reagents and controls. We also provide CE-marked in vitro diagnostic products to customers.
Detection Method:
Gel Detection
|
ABI Fluorescence Detection
|
Illumina MiSeq
|
| LymphoTrack™ |
LymphoTrack™ Assays are used to identify and track clonal B and T cell populations. |
||||||||||
| LeukoStrat™ |
LeukoStrat CE-marked in vitro diagnostic products are are used worldwide to determine the mutation status of the FLT3 and NPM1 biomarkers, providing information critical for assessing prognosis for patients with acute myeloid leukemia. |
||||||||||
| IdentiClone™ |
IdentiClone CE-marked in vitro diagnostic products are the molecular diagnostic products were developed and clinically validated by the BIOMED-2 Group. They are used to test DNA extracted from a variety of patient samples and have demonstrated clinical efficacy identifying clonal populations in suspect lymphoproliferations. |
||||||||||
| IGH Somatic Hypermutation Tests |
The CE-marked IGH Somatic Hypermutation Assays are used to identify clonal rearrangements of the immunoglobulin heavy (IGH) chain gene and determine the somatic mutation status of the variable (V) gene sequence in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) specimens. |
||||||||||